2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3–Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)

References

• Savoie N , BoothBP, BradleyTet al. 2008 White Paper: The 2nd Calibration and Validation Group Workshop on Recent Issues in Good Laboratory Practice Bioanalysis. Bioanalysis1(1), 19–30 (2009).
   PubMed Web of Science ®Google Scholar
• Savoie N , GarofoloF, van AmsterdamPet al. 2009 White Paper on Recent Issues in Regulated Bioanalysis from the 3rd Calibration and Validation Group Workshop. Bioanalysis2(1), 53–68 (2010).
   PubMed Web of Science ®Google Scholar
• Savoie N , GarofoloF, van AmsterdamPet al. 2010 White Paper on Recent Issues in Regulated Bioanalysis and Global Harmonization of Bioanalytical Guidance. Bioanalysis2(12), 1945–1960 (2010).
   PubMed Web of Science ®Google Scholar
• Garofolo F , RocciM, DumontIet al. 2011 White Paper on Recent Issues in Bioanalysis and Regulatory Findings from Audits and Inspections. Bioanalysis3(18), 2081–2096 (2011).
   PubMed Web of Science ®Google Scholar
• DeSilva B , GarofoloF, RocciMet al. 2012 White Paper on Recent Issues in Bioanalysis and Alignment of Multiple Guidelines. Bioanalysis4(18), 2213–2226 (2012).
   PubMed Web of Science ®Google Scholar
• Stevenson L , RocciM, GarofoloFet al. 2013 White Paper on Recent Issues in Bioanalysis: “Hybrid”–the best of LBA & LC/MS. Bioanalysis5(23), 2903–2918 (2013).
   PubMed Web of Science ®Google Scholar
• Fluhler E , HayesR, GarofoloFet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1–small molecules by LCMS). Bioanalysis6(22), 3039–3049 (2014).
   PubMed Web of Science ®Google Scholar
• Dufield D , NeubertH, GarofoloFet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2–hybrid LBA/LCMS, ELN & regulatory agencies’ input). Bioanalysis6(23), 3237–3249 (2014).
   PubMed Web of Science ®Google Scholar
• Stevenson L , AmaravadiL, MylerHet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3–LBA and immunogenicity). Bioanalysis6(24), 3355–3368 (2014).
   PubMed Web of Science ®Google Scholar
• Welink J , FluhlerE, HughesNet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1–small molecules by LCMS). Bioanalysis7(22), 2913–2925 (2015).
   PubMed Web of Science ®Google Scholar
• Ackermann B , NeubertH, HughesNet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2–hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis7(23), 3019–3034 (2015).
   PubMed Web of Science ®Google Scholar
• Amaravadi L , SongA, MylerHet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3–LBA, biomarkers and immunogenicity). Bioanalysis7(24), 3107–3124 (2015).
   PubMed Web of Science ®Google Scholar
• Yang E , WelinkJ, CapeSet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1–small molecules, peptides and small molecule biomarkers by LCMS). Bioanalysis8(22), 2363–2378 (2016).
   PubMed Web of Science ®Google Scholar
• Song A , LeeA, GarofoloFet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2–Hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis8(23), 2457–2474 (2016).
   PubMed Web of Science ®Google Scholar
• Richards S , AmaravadiL, PillutlaRet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3–LBA, biomarkers and immunogenicity). Bioanalysis8(23), 2475–2496 (2016).
   PubMed Web of Science ®Google Scholar
• Welink J , YangE, HughesNet al. 2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines ‘Scientific’? (Part 1–LCMS: small molecules, peptides and small molecule biomarkers). Bioanalysis9(22), 1807–1825 (2017).
   PubMed Web of Science ®Google Scholar
• Neubert H , SongA, LeeAet al. 2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs). Bioanalysis9(23), 1895–1912 (2017).
   PubMed Web of Science ®Google Scholar
• Gupta S , RichardsS, AmaravadiLet al. 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3–LBA: immunogenicity, biomarkers and PK assays). Bioanalysis9(24), 1967–1996 (2017).
   PubMed Web of Science ®Google Scholar
• Welink J , XuY, YangEet al. 2018 White Paper on Recent Issues in Bioanalysis: ‘A global bioanalytical community perspective on last decade of incurred samples reanalysis (ISR)’ (Part 1–small molecule regulated bioanalysis, small molecule biomarkers, peptides & oligonucleotide bioanalysis). Bioanalysis10(22), 1781–1801 (2018).
   PubMed Web of Science ®Google Scholar
• Neubert H , OlahT, LeeAet al. 2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2–PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies’ inputs on bioanalysis, biomarkers and immunogenicity). Bioanalysis10(23), 1897–1917 (2018).
   PubMed Web of Science ®Google Scholar
• Stevenson L , RichardsS, PillutlaRet al. 2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3–LBA/cell-based assays: immunogenicity, biomarkers and PK assays). Bioanalysis10(24), 1973–2001 (2018).
   PubMed Web of Science ®Google Scholar
• Garofolo W , SavoieN. The Decennial Index of the White Papers in Bioanalysis: ‘A Decade of Recommendations (2007–2016)’. Bioanalysis9(21), 1681–1704 (2017).
   PubMed Web of Science ®Google Scholar
• Fandozzi C , EvansC, WilsonAet al. 2019 White Paper on Recent Issues in Bioanalysis: Chromatographic Assays (Part 1–Innovation in Small Molecules and Oligonucleotides & Mass Spectrometric Method Development Strategies for Large Molecule Bioanalysis). Bioanalysis11(22), 2029–2048 (2019).
   PubMed Web of Science ®Google Scholar
• Booth B , StevensonL, PillutlaRet al. 2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (Part 2–Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies’ Input on Bioanalysis, Biomarkers and Immunogenicity). Bioanalysis11(23), 2099–2132 (2019).
   PubMed Web of Science ®Google Scholar
• Piccoli S , MehtaD, VitalitiAet al. 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3–Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62). Bioanalysis11(24), 2207–2244 (2019).
   PubMed Web of Science ®Google Scholar
• US FDA, Center for Drug Evaluation and Research . Guidance for Industry: Immunogenicity Testing of Therapeutic Proteins Products–Developing and Validating Assays for Anti-Drug Antibody Detection (2019). https://www.fda.gov/media/119788/download
   Google Scholar
• Shankar G , DevanarayanV, AmaravadiLet al. Recommendation for the validation of immunoassay used for detection of host antibodies against bioanalytical products. J. Pharm. Biomed. Anal.48, 1267–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Smith BP , VandenhendeFR, DeSanteKAet al. Confidence interval criteria for assessment of dose proportionality. Pharm. Res.17(10), 1278–1283 (2000).
   PubMed Web of Science ®Google Scholar
• Hendriks J , StalsC, VersteilenAet al. Stability studies of binding and functional anti-vaccine antibodies. Bioanalysis6(10), 1385–1393 (2014).
   PubMed Web of Science ®Google Scholar
• Michaut L , LaurentN, KentschKet al. Stability of anti-immunotherapeutic antibodies in frozen human serum samples. Bioanalysis6(10), 1395–1407 (2014).
   PubMed Web of Science ®Google Scholar
• CLSI . CLSI Guideline H62: Validation of Assays Performed by Flow Cytometry (2019). https://www.wrib.org/PDFs/Flow_H62_Proposed_Draft-190919.pdf
   Google Scholar
• Cossarizza A , ChangH-D, RadbruchAet al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology49(10), 1457–1973 (2019).
   PubMed Web of Science ®Google Scholar
• Perfetto SP , AmbrozakD, NguyenRet al. Quality assurance for polychromatic flow cytometry. Nat. Protoc.1(3), 1522–1530 (2006).
   PubMed Web of Science ®Google Scholar
• Perfetto SP , AmbrozakD, NguyenRet al. Quality assurance for polychromatic flow cytometry using a suite of calibration beads. Nature Protocols7, 2067–2079 (2012).
   PubMed Web of Science ®Google Scholar
• Bustin SA , BenesV, GarsonJAet al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem.55(4), 611–622 (2009).
   PubMed Web of Science ®Google Scholar
• CLSI . CLSI.org
   Google Scholar
• Gorovits B , KorenE. Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics. BioDrugs33(3), 275–284 (2019).
   PubMed Web of Science ®Google Scholar
• Potthoff B , McBlaneF, SpindeldreherSet al. A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel. J. Imm. Meth.476, 112692 (2020). 10.1016/j.jim.2019.112692
   Google Scholar
• EMA 2018 . Assessment Report: Kymriah (Tisagenleucel) (2018). https://www.ema.europa.eu/en/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf
   Google Scholar
• Lamers CHJ , KlaverY, GratamaJWet al. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. Biochem. Soc. Trans.44(3), 951–959 (2016).
   PubMed Web of Science ®Google Scholar
• Annika CK et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J.Immunol. Methods283(1-2), 141–153 (2003).
   PubMed Web of Science ®Google Scholar
• Theresa LW et al. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res.9(2), 641–649 (2003).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . EMA General Principles to Address Virus and Vector Shedding (EMEA/CHMP/ICH/449035/2009) (2009). https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-10.pdf
   Google Scholar
• US FDA, Center for biologics evaluation and research . Guidance for industry: Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products (2015). www.fda.gov/media/89036/download
   Google Scholar
• Pharmaceuticals and Medical Devices Agency . PMDA Japan Guidance on ensuring the quality and safety of products for gene therapy (2019). https://www.pmda.go.jp/files/000235607.pdf
   Google Scholar
• Rangarajan S , WalshL, LesterWet al. AAV5-Factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med.377(26), 2519–2530 (2017).
   PubMed Web of Science ®Google Scholar
• Zen Z , EspinozaY, BleuT, SommerJM, WrightJF. Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum. Gene Ther.15(7), 709–715 (2004).
   PubMed Web of Science ®Google Scholar
• Bustin S , HuggettJ. qPCR primer design revisited. Biomol. Detect. Quantif.14, 19–28 (2017).
   PubMedGoogle Scholar
• Huggett JF et al. The Digital MIQE Guidelines: minimum information for publication of quantitative digital PCR experiments. Clin. Chem.59(6), 892–902 (2013).
   PubMed Web of Science ®Google Scholar
• Wang D , TaiPWL, GaoG. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discovery18, 358–378 (2019).
   PubMed Web of Science ®Google Scholar
• Gorovits B , FiscellaM, HavertMet al. Recommendations for the Development of Anti-Viral Vector Neutralizing Antibody Assays. AAPS J.22(2), 24 (2020).
   PubMed Web of Science ®Google Scholar
• US FDA, Center for Biologics Evaluation and Research . Guidance for Industry: Human Gene therapy for Rare Diseases (2020). https://www.fda.gov/media/113807/download
   Google Scholar
• Janetzki S , PanageasKS, Ben-PoratLet al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother.57(3), 303–315 (2008).
   PubMed Web of Science ®Google Scholar
• Janetzki S , PriceL, SchroederHet al. Guidelines for the automated evaluation of Elispot assays. Nat. Protoc.10(7), 1098–1115 (2015).
   PubMed Web of Science ®Google Scholar
• Immudex . Proficiency Panels:How Well Do You Perform T-cell Immune Monitoring?​https://www.immudex.com/proficiency-panels.aspx
   Google Scholar
• ICH . ICH Q2R1: Validation of Analytical Procedures: Text and Methodology (2005). https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf
   Google Scholar
• European Medicines Agency . EMA Guideline on Immunogenicity Assessment of Therapeutic Proteins.EMEA/CHMP/BMWP/14327/2006 Rev 1 (2017). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf
   Google Scholar
• Calcedo R , MorizonoH, WangLet al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccine Immunol.18, 1586–1588 (2011).
   PubMed Web of Science ®Google Scholar
• Mingozzi F , ChenY, EdmonsonSCet al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther.20, 417–424 (2013).
   PubMed Web of Science ®Google Scholar
• Calcedo R , VandenbergheLH, GaoGet al. Worldwide epidemiology of neutralizing to adenoassociated viruses. J. Infect. Dis.199, 381–390 (2009).
   PubMed Web of Science ®Google Scholar
• Finco D , BaltrukonisD, Clemens-EganAet al. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J. Pharm. Biomed. Analysis54(2), 351–358 (2011).
   PubMed Web of Science ®Google Scholar
• Wu Y , AkhgarA, LiJJet al. Selection of a ligand-binding neutralizing antibody assay for benralizumab: comparison with an antibody-dependent cell-mediated cytotoxicity (ADCC) cell-based assay. AAPS J.20(3), 49 (2018).
   PubMed Web of Science ®Google Scholar
• Wu B , ChungS, JiangXRet al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J.18(6), 1335–1350 (2016).
   PubMed Web of Science ®Google Scholar
• USP-NF <1106.1> Immunogenicity Assays–Design and Validation of Assays to Detect Anti-Drug Neutralizing Antibody (2015).
   Google Scholar
• US FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) . Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (2016). https://www.fda.gov/media/88622/download
   Google Scholar
• US FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) . Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (2015). https://www.fda.gov/media/82647/download
   Google Scholar
• US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine . Guidance for Industry, Bioanalytical Method Validation (2018). https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf
   Google Scholar
• US FDA, Center for Drug Evaluation and Research . Draft Guidance for Industry: Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products (2019). https://www.fda.gov/media/133014/download
   Google Scholar
• Devanarayan V , ToveyMG. Cut point and performance characteristics for anti-drug antibody assays. In: Detection and Quantification of Antibodies to Biopharmaceuticals.MichaelG ( Ed.). Tovey, Wiley (2011).
   Google Scholar
• Kurki P . Compatibility of immunogenicity guidance by the EMA and the US FDA. Bioanalysis11(17), 1619–1629 (2019).
   PubMed Web of Science ®Google Scholar
• Kubiak RJ , ZhangJ, RenP, YangH, RoskosLK. Excessive outlier removal may result in cut points that are not suitable for immunogenicity assessments. J. Imm. Meth.463, 105–111 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang J , ArendsRHGP, KubiakRJ, RoskoLK, LiangM, LeeN, ChenC-K, YangH. A new method for identification of outliers in immunogenicity assay cut point data. J. Imm. Meth.484–485, 112817 (2020).
   PubMed Web of Science ®Google Scholar
• Kubiak RJ , ZhangJ, ZhangJ, ZhuYet al. Correlation of screening and confirmatory results in tiered Immunogenicity testing by solution-phase bridging assays. J. Pharm. Biomed. Anal.74, 235–245 (2013).
   PubMed Web of Science ®Google Scholar
• Kubiak RJ , ArendsRGHP, LeeN, LiangM, ZhangJ, RoskosLK. Confirmatory cut point has limited ability to make accurate classifications in Immunogenicity assays. Bioanalysis12(4), 246–256 (2020).
   Web of Science ®Google Scholar
• Tovey MG , LallemandC. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther. Adv. Drug Safety2(3), 113–128 (2011).
   PubMedGoogle Scholar
• Jawa V , TerryF, GokemeijerJet al. T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation–updated consensus and review. Front. Immunol.11, 1301 (2020).
   PubMed Web of Science ®Google Scholar
• Rosenberg AS , SaunaZE. Immunogenicity assessment during the development of protein therapeutic. JPP70(5), 584–594 (2018).
   Google Scholar
• US FDA, Center for Biologics Evaluation and Research . Guidance for Industry: Human Gene Therapy for Rare Diseases (2020). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-rare-diseases
   Google Scholar
• Andrew CM et al. Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome. J. Immunol. Meth.440, 41–51 (2017).
   PubMed Web of Science ®Google Scholar
• Gupta S et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. EBioMedicine37, 366–373 (2018).
   PubMed Web of Science ®Google Scholar
• Bruce NR , MooJC. Antibodies as carrier proteins. Pharm. Res.15(11), 1652–1656 (1998).
   PubMed Web of Science ®Google Scholar
• Hogarth PM . Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol.14(6), 798–802 (2002).
   PubMed Web of Science ®Google Scholar
• Chauhan AK , MooreTL. T cell activation by terminal complex of complement and immune complexes. J. Biol. Chem.286(44), 38627–38637 (2011).
   PubMed Web of Science ®Google Scholar
• Rojas JR , TaylorRP, CunninghamMRet al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J. Pharm. Exp. Ther.313(2), 578–585 (2005).
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann. Rheum. Dis.72(1), 104–109 (2013).
   PubMed Web of Science ®Google Scholar
• Krishna M , StevenGN. Immunogenicity to biotherapeutics–the role of anti-drug immune complexes. Front. Immunol.7, 21 (2016).
   PubMed Web of Science ®Google Scholar
• Hoffmann E et al. Generation, characterization, and quantitative bioanalysis of drug/anti-drug antibody immune complexes to facilitate dedicated in vivo studies. Pharm. Res.36(9), 129 (2019).
   PubMed Web of Science ®Google Scholar
• van Schie KA et al. Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies. Ann. Rheum. Dis.77(10), 1471–1479 (2018).
   PubMed Web of Science ®Google Scholar
• Regenass-Lechner F et al. Immunogenicity, inflammation, and lipid accumulation in Cynomolgus monkeys infused with a Lipidated Tetranectin-ApoA-I fusion protein. Toxicol. Sci.150(2), 378–389 (2016).
   PubMed Web of Science ®Google Scholar
• Tada M , TakuoS, AkikoI-W. Development and characterization of an anti-rituximab monoclonal antibody panel. MAbs10(3), 370–379 (2018).
   PubMed Web of Science ®Google Scholar
• Labrijn AF et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov.18(8), 585–608 (2019).
   PubMed Web of Science ®Google Scholar
• Hoofring SA , LopezR, HockMBet al. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis5(9), 1041–1055 (2013).
   PubMed Web of Science ®Google Scholar
• Stubenrauch K , KunzelC, VogelR, TuerckD, SchickE, HeinrichJ. Epitope characterization of the ADA response directed against a targeted immunocytokine. J. Pharm. Biomed. Anal.114, 296–304 (2015).
   PubMed Web of Science ®Google Scholar
• Gorovits B , PengK, KrommingaA. Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics. BioDrugs34(1), 39–54 (2020).
   PubMed Web of Science ®Google Scholar
• Gorovits B et al. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J. Immunol. Methods408, 1–12 (2014).
   PubMed Web of Science ®Google Scholar
• Broders O , WesselsU, ZadakM, BeckmannR, StubenrauchK. Novel bioanalytical method for the characterization of the immune response directed against a bispecific F(ab) fragment. Bioanalysis12(8), 509–517 (2020).
   PubMed Web of Science ®Google Scholar
• Vainshtein I , SunB, RoskosLK, LiangM. A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains. J. Immunol. Methods477, 112688 (2020).
   PubMed Web of Science ®Google Scholar
• Shankar G , ArkinS, CoceaLet al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J.16(4), 658–673 (2014).
   PubMed Web of Science ®Google Scholar